Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Study ID: NCT00210379
Phase: PHASE2
Status: Completed

Conditions

Lymphoma, B Cell

Eligibility Criteria

Sex: MALE
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

rituximab — DRUG
CHOP — DRUG
intrathecal methotrexate — DRUG
radiotherapy — PROCEDURE

Study Details

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy

Key Dates

Start date: Nov 30, 2000
Status verified: Jul 2009
Primary completion: Nov 30, 2004
Completion: Mar 31, 2007

Study Design

Enrollment: 64 participants (actual)
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Primary Outcome Measure

Disease-free survival